Shiven B. Patel, MD, MBA, FACP, discusses how zidesamtinib compares with taletrectinib in ROS1-positive non–small cell lung cancer.
Shiven B. Patel, MD, MBA, FACP
Advertisement
Articles by Shiven B. Patel, MD, MBA, FACP
Shiven B. Patel, MD, MBA, FACP, discusses treatment considerations in patients with advanced squamous non–small cell lung cancer.
Advertisement
Latest Updated Articles
Dr. Patel on Treatment Considerations in Advanced Squamous NSCLCOctober 24th 2019
Advertisement
Advertisement
Trending on OncLive
1
Cardiovascular and Bleeding Risk With BTK Inhibitors in CLL
2
FDA Approves Durvalumab Plus Enfortumab Vedotin for Cisplatin-Ineligible MIBC
3
CHMP Recommends Approval of Belzutifan Plus Lenvatinib for Advanced ccRCC After PD-(L)1 Inhibition
4
Expanding Clinical Trial Access Through Community Oncology
5